

POLARIS QCDR IN COLLABORATION WITH THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – 2021 MEASURE SPECIFICATIONS

QOPI27

Measure #	QOPI27
Measure Title	Appropriate Antiemetic Therapy for High- and Moderate Emetic Risk Antineoplastic Agents
Measure Description	Percentage of cancer patients aged ≥18 years treated with high- or moderate-emetive risk antineoplastic agents who are administered appropriate pre-treatment antiemetic therapy
Denominator Exclusion	None
Denominator Exceptions	Denominator Exception Criteria 1: Patient allergy to neurokinin 1 (NK1) receptor antagonist, serotonin (5-HT3) receptor antagonist, dexamethasone, or olanzapine Denominator Exception Criteria 2: Patient allergy to 5-HT3 receptor antagonist, or dexamethasone
Denominator	Denominator Criteria 1: All patients aged ≥18 years diagnosed with cancer who receive high-emetive risk antineoplastic agents during cycle 1 of the patient's first chemotherapy regimen Denominator Criteria 2: All patients aged ≥18 years diagnosed with cancer who receive moderate-emetive risk antineoplastic agents during cycle 1 of the patient's first chemotherapy regimen Denominator Guidance: For guidance on determining emetic risk, please refer to Table 1, Emetic Risk of Single Intravenous Antineoplastic Agents in Adults (Hesketh, P.J., K. Bohlke, and M.G. Kris, Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract, 2017. 13(12): p. 825-830)
Numerator	Numerator Criteria 1: Patients who are administered prior to treatment a four-drug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine Numerator Criteria 2: Patients who are administered prior to treatment a two-drug combination of a 5-HT3 receptor antagonist, and dexamethasone
Numerator Exclusions	None
Number of Performance Rates to be calculated and submitted	1
Inverse Status	No
Proportional, CV, Ratio Status	Proportional
Risk Adjusted, if applicable	No
High Priority measure	No
Measure type	Process
Outcome measure	No
NQS Domain	Effective Clinical Care
NQF ID	N/A
Meaningful Measure Area	Appropriate use of Healthcare
Care Setting(s) to include Telehealth, if applicable	Outpatient Services

Copyright: ©2021 American Society of Clinical Oncology. All Rights Reserved. The American Society for Clinical Oncology (ASCO) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of ASCO, its members and the Polaris Qualified Clinical Data Registry for the purposes specified herein and for other ASCO purposes. It may not be used by other parties except with prior written approval of ASCO. Contact measurement@asco.org for licensing this measure.